Abstract Background and Objective While biosimilars are less expensive than their
originator biologics, various factors are known to impede their uptake in clinical practice …

Background The availability of biosimilar medicines in Southern European markets has
allowed purchasing biologics at a lower cost for healthcare systems. However, the capacity …

A clinical guideline is a document with the aim of guiding decisions based on evidence
regarding diagnosis, management and treatment in specific areas of healthcare. Specific to …

Introduction After 17 years on the market, biosimilar medicines have contributed significantly
to the sustainability of healthcare in Spain, providing cost-effective treatment options and …

As the voice of cancer care clinicians and the patients they serve, ASCO has taken steps to
elevate awareness about biosimilar products and their use in oncology. In 2018, ASCO …

Background Switching to biosimilars is an effective and safe practice in treating inflammatory
diseases; however, a nocebo effect may arise as a result of the way in which the switch is …

Tumor necrosis factor-alpha (TNF-⍺) antagonists are biological drugs with multiple
authorized biosimilars. Biosimilars are becoming critical to the financial sustainability of …

The aim of this study was to describe the opinions of patients undergoing treatment with
originator biologics and medical consultants managing their conditions and identify the …

Objective To improve knowledge about biosimilar medicines and to generate a consensus
framework on their use. Methods Qualitative study. A multidisciplinary group of experts in …

This issue of JAMA Dermatology includes an article by Phan et al1 presenting a systematic
review of biosimilars for the treatment of psoriasis. In consideration of the high frequency of …